Depo-subq Provera Injection, Suspension
Product Images NDC 0009-4709

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Depo-subq Provera (NDC 0009-4709). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pharmacia & Upjohn Company Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure A (Depo Subq Provera 01)

The text describes a prefilled syringe needle with a safety shield for protection. The needle has a diameter of 3/8" and a specified length.*

FDA Label Image

Figure B (Depo Subq Provera 02)

FDA Label Image

Figure C (Depo Subq Provera 03)

FDA Label Image

Figure D (Depo Subq Provera 04)

FDA Label Image

Figure E (Depo Subq Provera 05)

FDA Label Image

Figure F (Depo Subq Provera 06)

FDA Label Image

Figure G (Depo Subq Provera 07)

FDA Label Image

Figure H (Depo Subq Provera 08)

FDA Label Image

Figure I (Depo Subq Provera 09)

FDA Label Image

Figure J (Depo Subq Provera 10)

FDA Label Image

Figure K (Depo Subq Provera 11)

FDA Label Image

Figure L (Depo Subq Provera 12)

FDA Label Image

Figure M (Depo Subq Provera 13)

This is a collection of references to studies that have investigated the relationship between the use of DMPA (a type of birth control) and the risk of developing H- (not enough information provided to identify what H- means). The studies were conducted by Lee et al. in 1987, Paul et al. in 1989, WHO in 1991, Shapiro et al. in 2000, and Lie et al. in 2012. The data presented shows odds ratios for DMPA use greater than or equal to 12 months for different age groups. The odds ratios presented are measures of the increased risk for DMPA use, and the values shown in parentheses are the confidence intervals for those odds ratios.*

FDA Label Image

Figure N (Depo Subq Provera 14)

FDA Label Image

Figure O (Depo Subq Provera 15)

FDA Label Image

Chemical Structure (Depo Subq Provera 16)

FDA Label Image

Figure P (Depo Subq Provera 17)

This data appears to be a chart or graph showing values at different time intervals. The values decrease over time, with the highest being 150 and the lowest being 30. The other characters appear to be decorative lines or symbols. The text "quw/Bu)" is not readable, likely due to a scanning error.*

FDA Label Image

Figure Q (Depo Subq Provera 18)

FDA Label Image

Logo (Depo Subq Provera 19)

This text is a statement indicating that the product is distributed by Pharmacia & Upjohn Co, which is a division of Pfizer Inc located in NY.*

FDA Label Image

Logo (Depo Subq Provera 20)

This is a statement indicating that a company called Pharmacia & Upjohn Co, which is a division of Pfizer Inc located in NY, NY 10017 is responsible for distribution.*

FDA Label Image

Principal Display Panel (0.65 mL Syringe Label)

This is a medication called Depo-Suba which is a subcutaneous injection of medroxyprogesterone acetate. It is supplied in a 0.65 mL single-dose syringe with a concentration of 104 mg/mL. The manufacturer is Pharmacia & Upjohn Co. It should be stored at room temperature and not refrigerated. There is a lot/expiry number listed but it is not available in the text provided.*

FDA Label Image

Principal Display Panel (0.65 mL Syringe Carton)

This is a description of a medication called Depo-SubQ Provera 104, which comes in a prefilled syringe. Shake the medication before use. The medication contains various chemicals, such as medroxyprogesterone acetate and sodium phosphate. The dosage and usage guidelines are not provided in the text. The medication should be stored at controlled room temperature, between 20°C and 25°C, and should not be refrigerated. Contact details for pfizer.com are provided for more information.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.